Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a ...

The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Here are the five things you need to know, including Lyra's good news, Sanofi's acquisition, Mass. biotech jobs, inside Market Basket's board, AI, and hiring entry-level jobs.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

The French drugmaker has acquired Blueprint Medicines Corporation following its sale of health consumer brand Opella.

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Sanofi will gain Blueprint's Ayvakit, a treatment for systemic mastocytosis and gastrointestinal stromal tumors, among other therapies in its pipeline.

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Shares of Nurix Therapeutics rose after the company said it will receive a $15 million license extension fee from Sanofi for its STAT6 program. The stock climbed 11% to $11.76 on Monday. Shares have ...